|
|
 Previous Article | Table of Contents | Next Article 
Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy
and autologous bone marrow transplantation
GL Phillips, SN Wolff, RH Herzig, HM Lazarus, JW Fay, HS Lin, DC Shina, GP Glasgow, RC Griffith and CW Lamb
Division of Hematology, Washington University, St. Louis.
Twenty-six patients with progressive Hodgkin's disease after conventional
chemotherapy received intensive chemoradiotherapy and autologous bone
marrow transplantation (ABMT); 19 also received additional involved-field
radiotherapy. Twenty-one patients [81%, 95% confidence intervals (CI) 61%
to 94%] attained complete (n = 18) or partial responses. Ten patients (38%,
95% CI 20% to 59%) are disease- free a median of 4.5 years later (range 3.5
to 7.0 years), including seven patients with continuous complete responses.
The likelihood of overall response was not significantly influenced by any
clinical or treatment variable examined. However, there was a trend
favoring patients with higher Karnofsky scores, and higher scores were
associated with attainment of complete responses (P = .06 and P = .02,
respectively, Mann-Whitney U test). Both higher Karnofsky scores and
shorter durations of disease before transplantation were associated with
improved survival in a stepwise Cox multivariate analysis. The chief cause
of failure was progression at sites previously involved with Hodgkin's
disease. No patient relapsed in the marrow, and two of three patients with
a history of marrow involvement with Hodgkin's disease achieved durable
complete responses after transplantation. These data suggest that
inadequate pretransplant conditioning, and not the reinoculation of occult
tumor cells in the autologous marrow, caused most relapses. Fatal
treatment-related toxicity occurred in six patients. Three patients died of
idiopathic interstitial pneumonitis; each had previously received local
mediastinal irradiation before intensive chemoradiotherapy. Intensive
chemoradiotherapy and ABMT produces durable responses in some patients with
Hodgkin's disease incurable with conventional therapy. Use of such
therapies at the first sign of failure with conventional chemotherapy and
development of more effective conditioning regimens should further improve
results.
Volume 73,
Issue 8,
pp. 2086-2092,
06/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. N. Wolff, J. D. Hainsworth, and F. A. Greco
High-Dose Etoposide: From Phase I to a Component of Curative Therapy
J. Clin. Oncol.,
November 20, 2008;
26(33):
5310 - 5312.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Byrne and J. P. Gockerman
Salvage Therapy in Hodgkin's Lymphoma
Oncologist,
February 1, 2007;
12(2):
156 - 167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sureda, M. Constans, A. Iriondo, R. Arranz, M. D. Caballero, M. J. Vidal, J. Petit, A. Lopez, J. J. Lahuerta, E. Carreras, et al.
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse
Ann. Onc.,
April 1, 2005;
16(4):
625 - 633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. E. Lieskovsky, S. S. Donaldson, M. A. Torres, R. M. Wong, M. D. Amylon, M. P. Link, and R. Agarwal
High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices
J. Clin. Oncol.,
November 15, 2004;
22(22):
4532 - 4540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors
Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hematology,
January 1, 2003;
2003(1):
225 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Branson, R. Chopra, P. D. Kottaridis, G. McQuaker, A. Parker, S. Schey, R. K. Chakraverty, C. Craddock, D. W. Milligan, R. Pettengell, et al.
Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies
J. Clin. Oncol.,
October 1, 2002;
20(19):
4022 - 4031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sureda, R. Arranz, A. Iriondo, E. Carreras, J.J. Lahuerta, J. Garcia-Conde, I. Jarque, M.D. Caballero, C. Ferra, A. Lopez, et al.
Autologous Stem-Cell Transplantation for Hodgkin's Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group
J. Clin. Oncol.,
March 1, 2001;
19(5):
1395 - 1404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Bogart, C. Ungureanu, S. Ryu, C. T. Chung, and K. W. Zamkoff
Hematologic Toxic Reaction to Radiation Therapy Adjuvant to Autologous Peripheral Blood Stem Cell Transplantation for Recurrent or Refractory Hodgkin Disease
Radiology,
February 1, 2000;
214(2):
421 - 425.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Aristei and A. Tabilio
Total-Body Irradiation in the Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoproliferative Diseases
Oncologist,
October 1, 1999;
4(5):
386 - 397.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. S. Baker, B. G. Gordon, T. G. Gross, M. A. Abromowitch, E. R. Lyden, J. C. Lynch, J. M. Vose, J. O. Armitage, P. F. Coccia, and P. J. Bierman
Autologous Hematopoietic Stem-Cell Transplantation for Relapsed or Refractory Hodgkin's Disease in Children and Adolescents
J. Clin. Oncol.,
March 1, 1999;
17(3):
825 - 825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Aisenberg
Problems in Hodgkin's Disease Management
Blood,
February 1, 1999;
93(3):
761 - 779.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Vockerodt, M. Soares, H. Kanzler, R. Kuppers, D. Kube, M.-L. Hansmann, V. Diehl, and H. Tesch
Detection of Clonal Hodgkin and Reed-Sternberg Cells With Identical Somatically Mutated and Rearranged VH Genes in Different Biopsies in Relapsed Hodgkin's Disease
Blood,
October 15, 1998;
92(8):
2899 - 2907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Horning, N. J. Chao, R. S. Negrin, R. T. Hoppe, G. D. Long, W. W. Hu, R. M. Wong, B. W. Brown, and K. G. Blume
High-Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplantation for Recurrent or Refractory Hodgkin's Disease: Analysis of the Stanford University Results and Prognostic Indices
Blood,
February 1, 1997;
89(3):
801 - 813.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Yuen, S. A. Rosenberg, R. T. Hoppe, J. D. Halpern, and S. J. Horning
Comparison Between Conventional Salvage Therapy and High-Dose Therapy With Autografting for Recurrent or Refractory Hodgkin's Disease
Blood,
February 1, 1997;
89(3):
814 - 822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Grossbard and N. L. Harris
Case 10-1994- A 37-Year-Old Woman with Thrombocytopenia and a Paragastric Mass after Treatment for Hodgkin's Disease
N. Engl. J. Med.,
March 10, 1994;
330(10):
698 - 704.
[Full Text]
|
|
|
|
|
|
|
V. T. DeVita and S. M. Hubbard
Hodgkin's Disease
N. Engl. J. Med.,
February 25, 1993;
328(8):
560 - 565.
[Full Text]
|
|
|
|
|
|
|
S. C. Gulati and C. L. Bennett
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease
Ann Intern Med,
February 1, 1992;
116(3):
177 - 182.
[Abstract]
[PDF]
|
|
|
|
|
